Myriad Genetics ex-Chief Commercial Officer Brian Donnelly exits under separation agreement
MYGN•Myriad Genetics disclosed that Brian Donnelly’s employment ended Sept. 21, 2026, under a separation agreement dated Oct. 6. The agreement provides accelerated vesting for certain time-based equity awards and keeps performance-based awards outstanding, with potential vesting tied to results over two years.
1. Separation agreement
Myriad Genetics disclosed Donnelly’s departure as chief commercial officer, effective Sept. 16, 2026. His employment ended at the close of business on Sept. 21 under a separation agreement dated Oct. 6.
2. Equity awards
The agreement includes accelerated vesting for certain time-based equity awards over a two-year period from the separation date. Performance-based equity awards remain outstanding, with potential vesting tied to results achieved within two years of that date.
